A61K31/225

Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms

Disclosed herein are methods for (a) inhibiting, reducing, slowing, or preventing, the aging of a subject, (b) for treating, inhibiting, reducing, or preventing an age-related disease in the subject, and/or (c) for increasing the lifespan of the subject which comprise administering to the subject one or more glutarate compounds, such as α-ketoglutate, and/or one or more glutamate compounds, such as 2-hydroxypentanedioate, and compositions thereof.

INJECTABLE DRUG DELIVERY IMPLANT COMPOSITION AND METHOD OF USE THEREOF

Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.

INJECTABLE DRUG DELIVERY IMPLANT COMPOSITION AND METHOD OF USE THEREOF

Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.

TREATMENT METHODS AND FORMULATIONS

The present invention relates to methods for preventing, reducing, or treating the incidence and/or severity of a disorder caused by stress-induced cellular damage in the ear of a subject, such as vestibular disorders, hearing impairment, and conditions related to hair cell degeneration or death. Specifically, this invention pertains to formulations comprising probucol or a probucol ester, a bioavailability-enhancing compound comprising a bile acid, and optionally a carrier. The administration of these formulations can treat hearing loss and/or hair cell degeneration or death.

TREATMENT METHODS AND FORMULATIONS

The present invention relates to methods for preventing, reducing, or treating the incidence and/or severity of a disorder caused by stress-induced cellular damage in the ear of a subject, such as vestibular disorders, hearing impairment, and conditions related to hair cell degeneration or death. Specifically, this invention pertains to formulations comprising probucol or a probucol ester, a bioavailability-enhancing compound comprising a bile acid, and optionally a carrier. The administration of these formulations can treat hearing loss and/or hair cell degeneration or death.

Prodrug for therapeutic applications

The disclosure provides for prodrugs of Fingolimod that were designed to specifically prevent phosphorylation during circulation, hence avoiding bradycardia and lymphopenia. The disclosure further provides for the use of the prodrugs in the treatment of cancer and multiple sclerosis in subjects in need of treatment thereof.

Prodrug for therapeutic applications

The disclosure provides for prodrugs of Fingolimod that were designed to specifically prevent phosphorylation during circulation, hence avoiding bradycardia and lymphopenia. The disclosure further provides for the use of the prodrugs in the treatment of cancer and multiple sclerosis in subjects in need of treatment thereof.

AGENT FOR INDUCING REGRESSION OF TRIGLYCERIDE DEPOSIT ATHEROSCLEROSIS
20230210805 · 2023-07-06 · ·

The present invention provides an agent for inducing regression of triglyceride (TG) deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, an agent for improving blood flow in a patient with TG deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, and a pharmaceutical or food or drink product comprising the agent for inducing regression of TG deposit atherosclerosis or the agent for improving blood flow.

AGENT FOR INDUCING REGRESSION OF TRIGLYCERIDE DEPOSIT ATHEROSCLEROSIS
20230210805 · 2023-07-06 · ·

The present invention provides an agent for inducing regression of triglyceride (TG) deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, an agent for improving blood flow in a patient with TG deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, and a pharmaceutical or food or drink product comprising the agent for inducing regression of TG deposit atherosclerosis or the agent for improving blood flow.

METHODS FOR PALMAR OR PLANTAR ADMINISTRATION OF PHARMACEUTICAL COMPOSITIONS
20220401412 · 2022-12-22 ·

Disclosed herein are methods for palmar or plantar administration of anticholinergic compounds to a subject in need thereof. Also disclosed herein are methods of treating palmar or plantar hyperhidrosis in a subject in need thereof by administering anticholinergic compounds to the palmar or plantar skin of the subject.